Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the fourth NHLBI workshop. Am J Respir Crit Care Med. 2001;164(11):2120–6.PubMed
Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New Engl J Med. 2009;360(25):2605–15.PubMedCrossRef
Bishop JF, Murnane MP, Owen R. Australia’s winter with the 2009 pandemic influenza A (H1N1) virus. New Engl J Med. 2009;361(27):2591–4.PubMedCrossRef
CDC. Update: influenza activity—United States, 2009–10 season. Morb Mortal Wkly Rep. 2010;59(29):901–8.
Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45(2):234–40.PubMedCrossRef
Althoff K, Gange S, Sharp G, et al. Elevated 2009 H1N1 antibody titers in HIV-infected and uninfected women in the US: a sero-study, March 1 to September 30, 2009 [abstract]. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010:#807LB.
• Kok J, Tudo K, Blyth CC, Foo H, Hueston L, Dwyer DE. Pandemic (H1N1) 2009 influenza virus seroconversion rates in HIV-infected individuals. J Acquir Immune Defic Syndr. 2011;56(2):91–4. This Australian study measured the post-pandemic seroprevalence and seroconversion rates of pH1N1 among HIV-infected adults and determined that these rates were similar to those reported from the general community. CD4 cell counts and HIV viral loads were not statistically different between patients who seroconverted and those who did not
Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, Dwyer DE. Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS One. 2010;5(9):e12562.PubMedCrossRef
Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 2011;25(2):177–83.PubMedCrossRef
• Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 Monovalent AS03-Adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52(2):248–56. This report compared immunogenicity of an adjuvanted pH1N1 vaccine in HIV-infected patients compared with solid-organ transplant recipients and healthy individuals and found that antibody response was similar between HIV-infected persons and healthy individuals
UNAIDS. Report on the global AIDS epidemic 2008: HIV and AIDS estimates and data, 2007 and 2001. Available from: http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp211_234_en.pdf
. Accessed 18 Mar 2010.
Oliveira W, Carmo E, Penna G, et al. Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI). Euro Surveill. 2009;14(42):19362.
Fagard C, Launay O, Boucherie C, et al. H1N1 pandemic flu: incidence and characteristics in HIV-infected adults [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#905.
•• Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ. 2011;60(1):1–24. This report updates recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding the use of antiviral agents for the prevention and treatment of influenza. This report contains information on treatment and chemoprophylaxis of influenza virus infection and provides a summary of the effectiveness and safety of antiviral treatment medications.
Campos-Loza A, Soto-Ramirez L, Sierra-Madero J, et al. New swine origin influenza A in HIV-infected patients during the 2009 outbreak in Mexico City [abstract]. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010:#801.
Martinez E, Marcos M, Hoyo-Ulloa I, et al. Influenza A H1N1 in HIV-infected adults. HIV Med. 2011;12(4):236–45.PubMedCrossRef
• Ormsby CE, de la Rosa-Zamboni D, Vazquez-Perez J, et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS. 2011;25(4):435–9. This study at a tertiary referral center in Mexico City described the clinical outcomes of 30 HIV-infected patients with pH1N1 illness. A significant proportion of these patients had advanced HIV infection, and clinical outcomes were more severe in patients not receiving HAART and patients with concomitant OIs
Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206–16.PubMedCrossRef
Isais F, Lye D, Llorin R, et al. Pandemic (H1N1) 2009 influenza in HIV-infected adults: clinical features, severity, and outcome. J Infect. 2010;61(5):437–40.PubMedCrossRef
Perez CM, Dominguez MI, Ceballos ME, et al. Pandemic influenza A (H1N1) in HIV-1-infected patients. AIDS. 2010;24(18):2867–9.PubMedCrossRef
• Peters P, Skarbinski J, Louie J, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (H1N1)-United States, spring and summer 2009. Clin Infect Dis. 2011;52(S1):S183–8. This manuscript described the clinical findings of HIV-infected patients hospitalized with pH1N1 in the United States. Hospitalized HIV-infected influenza patients experienced similar rates of ICU admission and death compared with HIV-uninfected patients. This study supports current recommendations to use early empiric influenza antiviral treatment for HIV-infected patients with suspected influenza or pneumonia
• Riera M, Payeras A, Marcos MA, et al. Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS. 2010;24(16):2461–7. This study evaluated the clinical presentation and prognosis of HIV-infected patients hospitalized with pH1N1 infection in Spain. The majority of HIV-infected patients were on HAART and had high CD4 cell counts. In this context the clinical outcomes in HIV-infected patients were similar to non–HIV-infected patients
Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160(21):3243–7.PubMedCrossRef
Shelhamer JH, Gill VJ, Quinn TC, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med. 1996;124(6):585–99.PubMed
•• Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003–32. An expert panel of the Infectious Diseases Society of America developed these evidence-based guidelines that encompass diagnostic issues and treatment and chemoprophylaxis for seasonal influenza. They are intended for use by physicians in all medical specialties with direct patient care
CDC. Guidance for clinicians on the use of rapid influenza diagnostic tests for the 2010–2011 influenza season. Available at http://www.cdc.gov/flu/pdf/professionals/diagnosis/clinician_guidance_ridt.pdf
. Accessed 26 Apr 2011.
CDC. Influenza symptoms and laboratory diagnostic procedures. Available at http://www.cdc.gov/flu/professionals/diagnosis/labprocedures.htm
. Accessed 26 Apr 2011.
CDC. Role of laboratory diagnosis of influenza. Available at http://www.cdc.gov/flu/professionals/diagnosis/labrole.htm
. Accessed 26 Apr 2011.
Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J. 2003;22(2):164–77.PubMed
Storch GA. Rapid diagnostic tests for influenza. Curr Opin Pediatr. 2003;15(1):77–84.PubMedCrossRef
•• Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. New Engl J Med. 2010;362(18):1708–19. This article from the Writing Committee of the WHO Consultation on the Clinical Aspects of Pandemic (H1N1) 2009 Influenza reviewed key issues for clinicians regarding epidemiology, pathogenesis, clinical features, diagnosis, and management of pH1N1 infections
Blyth CC, Iredell JR, Dwyer DE. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. New Engl J Med. 2009;361(25):2493.PubMedCrossRef
• Kok J, Blyth CC, Foo H, et al. Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol. 2009;48(1):290–1. This study reports reduced sensitivity of rapid antigen tests in detecting pH1N1 virus compared with seasonal influenza subtypes (53% vs 74%), highlighting that negative rapid influenza diagnostic test results should be confirmed with alternative tests if definitive diagnosis is needed
Louie JK, Guevara H, Boston E, et al. Rapid influenza antigen test for diagnosis of pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16(5):824–6.PubMed
• Klein NC, Chak A, Chengot M, Johnson DH, Cunha BA. Fatal case of pneumonia associated with pandemic (H1N1) 2009 in HIV-positive patient. Emerg Infect Dis. 2010;16(1):149–50. This report of a fatal case of pneumonia associated with pandemic (H1N1) 2009 in an HIV-positive patient illustrates the limitations of rapid influenza diagnostic tests (this patient had a false-negative result) and the importance of early empiric influenza antiviral treatment if influenza is suspected
Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2009;53(5):619–24.
•• Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17. The CDC recommends routine HIV screening of adults, adolescents, and pregnant women in health care settings, and hospital admission for influenza presents an important opportunity for HIV testing in patients aged 13–64 years. In addition, acute HIV infection should be considered in patients with “flu-like” symptoms (especially in patients who report high-risk behavior for HIV infection) and can be diagnosed by detecting HIV RNA in plasma from persons with a negative or indeterminate HIV antibody test
Dosekun O, Kober C, Richardson D, Parkhouse A, Fisher M. It’s not all swine flu…are we missing opportunities to diagnose primary HIV infection in patients with flu symptoms? Int J STD AIDS. 2010;21(2):145–6.PubMedCrossRef
Barchi E, Prati F, Parmeggiani M, Tanzi ML. Pandemic (H1N1) 2009 and HIV co-infection. Emerg Infect Dis. 2010;16(10):1643–4.PubMed
Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001;183(1):23–35.PubMedCrossRef
Weintrob AC, Giner J, Menezes P, et al. Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med. 2003;163(17):2097–100.PubMedCrossRef
Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32(12):1784–91.PubMedCrossRef
Neuzil KM, Reed GW, Mitchel Jr EF, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999;281(10):901–7.PubMedCrossRef
Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161(3):441–6.PubMedCrossRef
Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896–902.PubMedCrossRef
CDC. Patients hospitalized with 2009 pandemic influenza A (H1N1)—New York City, May 2009. JAMA. 2010;303(7):604–7.
Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. New Engl J Med. 2009;361(20):1935–44.PubMedCrossRef
Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872–9.PubMedCrossRef
Fuhrman C, Bonmarin I, Paty A, et al. Severe hospitalised 2009 pandemic influenza A (H1N1) cases in France, 1 July–15 November 2009. Euro Surveill. 2010;15(2):19463.
Nguyen TQ, Gwynn RC, Kellerman SE, et al. Population prevalence of reported and unreported HIV and related behaviors among the household adult population in New York City, 2004. AIDS. 2008;22(2):281–7.PubMedCrossRef
Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis. 2010;50(11):1498–504.PubMedCrossRef
Fowlkes AL, Arguin P, Biggerstaff MS, et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April–July 2009. Clin Infect Dis. 2011;52 Suppl 1:S60–8.PubMedCrossRef
• Archer B, Cohen C, Naidoo D, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill. 2009;14(42):19369. This report of 91 pH1N1-related fatalities from South Africa reported that 53% of patients were HIV-infected, but tuberculosis infection and pregnancy were also common. Although CD4 cell counts and comorbid conditions were not reported for HIV-infected patients who died of confirmed pH1N1, this report raises concern that HIV infection could increase influenza mortality in certain settings.
Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. New Engl J Med. 2010;362(1):86–7.PubMed
Alonso M, Rodriguez-Sanchez B, Giannella M, et al. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J Clin Virol. 2011;50(2):114–8.PubMedCrossRef
Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis. 2011;17(2):255–7.PubMed
Infectious Diseases Society of America. Influenza H1N1: frontline questions and expert opinion answers. Arlington: Infectious Diseases Society of America; 2009. Available from: http://www.idsociety.org/Content.aspx?id=15743
. Accessed 16 Mar 2011.
Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. New Engl J Med. 1997;337(13):874–80.PubMedCrossRef
Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. 1999;180(2):254–61.PubMedCrossRef
Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355(9218):1845–50.PubMedCrossRef
Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283(8):1016–24.PubMedCrossRef
McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568–75.PubMedCrossRef
Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880–7.PubMedCrossRef
Lee N, Chan PKS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492–500.PubMedCrossRef
Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282(13):1240–6.PubMedCrossRef
CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009. Morb Mortal Wkly Rep. 2009;58(35):969–72.
Hill-Cawthorne GA, Schelenz S, Lawes M, Dervisevic S. Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system. Emerg Infect Dis. 2010;16(7):1185–6.PubMedCrossRef
King Jr JC, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000;181(2):725–8.PubMedCrossRef
• Feiterna-Sperling C, Edelmann A, Nickel R, et al. Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children. Clin Infect Dis. 2010;51(11):e90–4. This pH1N1 outbreak investigation among 15 HIV-infected children in Germany documents duration of viral shedding similar to what has been reported in the general population and demonstrates reduced duration of shedding with oseltamivir treatment in this population
Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(Suppl B):23–9.PubMedCrossRef
Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. New Engl J Med. 2000;343(18):1282–9.PubMedCrossRef
Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285(6):748–54.PubMedCrossRef
Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1–62.PubMed
•• Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med. 2008;9(1):57–61. This meta-analysis assessed clinical efficacy of seasonal influenza vaccine in HIV-infected persons and found the pooled relative risk reduction in prevention of influenza by vaccination from three studies (including one randomized controlled trial) was 65% (95% CI 36%–82%)
• Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011;52(1):128–37. This randomized, double-blind, placebo-controlled trial of trivalent, inactivated influenza vaccine among HIV-infected adults was the first influenza vaccine trial reported from Africa and demonstrated an efficacy of 75.5% without affecting CD4 cell count or HIV viral load
• Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52(1):138–46. This prospective study compared immunogenicity of monovalent pH1N1 vaccine in HIV-infected versus HIV-uninfected persons and found that, despite having high CD4 cell counts, HIV-infected persons were less likely to achieve protective antibody titer
Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2001;65(4):644–8.PubMedCrossRef
Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma. 1999;32(3–4):369–74.PubMed
Kroon FP, Rimmelzwaan GF, Roos MT, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12(17):F217–23.PubMedCrossRef
Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182(6):1727–37.PubMedCrossRef
Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20 Suppl 5:B29–32.PubMedCrossRef
Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48(10):1402–12.PubMedCrossRef
Tebas P, Frank I, Lewis M, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010;24(14):2187–92.PubMedCrossRef
Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(2):167–73.PubMed
Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis. 2006;6:138.PubMedCrossRef
Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS. 2010;24(9):F31–5.PubMedCrossRef
Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52(1):122–7.PubMedCrossRef
Durier C, Desaint C, Colin de Verdiere N, et al. Durability of immune response after vaccination with 2 doses of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant in HIV+ adults: ANRS 151 randomized HIFLUVAC trial [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#909.
Orlando G, Pariani E, Mazza F, et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS. 2010;24(13):2142–3.PubMedCrossRef
Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6(1):e16496.PubMedCrossRef
Cooper C, Klein M, Walmsley S, Hasse D, Scheifele D, Network PHAoC-CIoHRIR. A randomized trial to compare the immunogenicity and efficacy of adjuvanted pandemic H1N12009 vaccine with or without booster in HIV+ adults [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#907.
Santini-Oliveira M, Camacho L, Souza T, et al. Immunogenicity to an H1N1 adjuvanted influenza vaccine in HIV-infected adults: 2 single vs. 2 double doses: the VIP-H1N1 study [abstract]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011:#910.